Leading Research BioTech Company

This is a leading research BioTech company specializing in the design, manufacturing, and marketing of affinity blood filtration products. The company has an excellent safety record, having completed over 2500 clinical treatments. Their core innovation is a highly advanced hemofiltration device that utilizes patented and proprietary biomimetic technology to rapidly remove harmful agents such as bacteria, fungi, toxins, viruses, and sepsis mediators from a patient's bloodstream. The global sepsis market presents a significant opportunity, with over 30 million cases annually. Beyond sepsis treatment, the technology has potential applications as a countermeasure for bioweapons attacks (e.g., COVID-related), treating PDAC cancer, preventing side effects of ECMO and cardiopulmonary bypass, and in diagnostics, blood banking, and bioprocessing. The company boasts strong management and impressive gross profit margins exceeding 85%.